Overview

Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this prospective randomized study,all patients in control group will receive blank placebo ,all patients in test group will receive tongxinluo.All patients will be followed up for one year.
Phase:
Phase 4
Details
Lead Sponsor:
Han Yaling
Treatments:
Clopidogrel